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A B S T R A C T
Objective: To evaluate the effects of surface electrical stimulation (SES) and to compare them with the
effects of the intravaginal electrical stimulation (IVES) in women with stress urinary incontinence (SUI).
Study design: This randomized controlled study included 48 women aged over 50 years, who complained
of SUI evaluated according to two structured questions of King’s Health Questionnaire (KHQ) and who
had not previously undergone physical therapy for SUI. The calculation of the sample size estimated a
sample of 45 volunteers with a signiﬁcance level of 5% and statistical power of 90%. The women were
randomized to: Surface Electrical Stimulation Group (SESG) (n = 15), Intravaginal Electrical Stimulation
Group (IVESG) (n = 15) and Control Group (CG) (n = 15). Subjects in the intervention groups were treated
with the same parameters of electrical stimulation for 12 sessions. The SESG had four silicone electrodes
ﬁxed in the suprapubic and ischial tuberosity regions. The IVES group used an intravaginal electrode. The
CG did not receive any treatment during the corresponding time. They were evaluated before and after
treatment by a physical therapist who was blind to group allocation. The primary outcomes were urinary
leakage, pressure and strength of pelvic ﬂoor muscle (PFM) contraction. The secondary outcome was
quality of life (QOL) evaluated by KHQ. Forty-ﬁve women completed the study and were included in the
analysis. Statistical analysis was performed using the Wilcoxon test for intragroup analysis and Kruskal–
Wallis and Mann–Whitney tests for intergroup analysis (p < 0.05).
Results: There was signiﬁcant improvement in urinary loss and pressure of contraction in the SESG and
IVESG. PFM strength increased only in the IVESG. Intergroup analysis found differences after the
treatment in: urinary leakage between the SESG and CG (p < 0.001) and the IVESG and CG (p < 0.001).
Regarding QOL, there was signiﬁcant reduction in the incontinence impact, limitations of daily activities,
physical limitation, emotion, sleep and disposition and severity domains in the SESG (all p < 0.02) and
IVESG (all p < 0.04) after the treatments.
Conclusion: SES and IVES are important treatments to improve the SUI. Both improved the QOL, urinary
leakage, and strength and pressure of PFM contraction.
 2013 Elsevier Ireland Ltd. All rights reserved.
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The International Continence Society recommended physical
therapy as ﬁrst-line treatment for urinary incontinence (UI) [1]
because it promotes good results, has low costs, is minimally
invasive and has a low rate of side effects [2,3]. In a systematic§ Registration number: The trial is registered at Brazilian Clinical Trials Registry
(ReBEC), number ‘‘RBR-7gt9pb’’.
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http://dx.doi.org/10.1016/j.ejogrb.2013.11.023review, Dumoulin and Hay-Smith [4] reported that pelvic ﬂoor
muscle (PFM) training is the treatment with the best clinical
results.
Bø and Sherburn [5] reported that 30% of women did not
perform PFM contraction correctly during evaluation, compromis-
ing the results of PFM training, so in order to improve the
proprioception of PFM the use of some equipment is indicated,
such as vaginal cones, biofeedback and electrical stimulation (ES)
[4,6–8], which can be performed with intravaginal, anal and
superﬁcial electrodes.
Studies have evaluated the effects of intravaginal electrical
stimulation (IVES) treatment [8–10] in the treatment of stress
urinary incontinence (SUI). This treatment is used more in clinical
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to sterilize the electrode and the risk of vaginal and urinary
infection [8,11,12].
Another possibility for treatment is surface electrical stimula-
tion (SES) [13–16] which can promote PFM contraction, increasing
its strength and improving SUI [3,6,17,18]. This treatment is cheap,
less embarrassing and does not require sterilization [16].
Nevertheless SES is a modality of therapy that still is little tackled
in clinical studies. Moreover, we did not ﬁnd studies that compared
the effects of SES and IVES treatment, which showed the need for
this present study.
The purpose of this study, therefore, was to investigate the
effect of SES and compare it with IVES in women with SUI. Our
hypothesis is that SES treatment will demonstrate a similar
improvement of SUI, when compared to IVES treatment.
2. Materials and methods
2.1. Subjects
This was a randomized controlled study performed from
January 2012 to March 2013 and conducted at the Laboratory of
Research in Women’s Health, Federal University of Sa˜o Carlos. The
local ethics committee approved the study (405/2010), which is in
agreement with the Declaration of Helsinki.
The sample size was calculated considering the values of pad
test (in grams) from previous data on a pilot study of SES treatment
[16]. At a signiﬁcance level of 5% and power of 90%, it was
estimated to require a sample of at least 45 people.
The inclusion criteria were women aged over 50 years, who
complained of urinary leakage on stress and who had not
undergone physical therapy for UI. Women with symptoms of
urgency UI and mixed UI were excluded. Two questions were used
to determine patient eligibility. The ﬁrst question was: ‘‘During the
past month, have you involuntarily got wet while performing some
kind of physical exertion, e.g. coughing, lifting, sneezing or
laughing?’’ The second question was: ‘‘During the past month,
have you experienced such a strong urge to urinate that it was
impossible to get to the toilet in time?’’ Only women who
answered ‘‘yes’’ just to the ﬁrst question were recruited. The
sensitivity/speciﬁcity are 0.85/0.91 and 0.90/0.90 for the ﬁrst and
second questions, respectively [19].
Exclusion criteria included latex allergies, vaginal or urinary
infections, pelvic organ prolapse greater than grade II [20], inability
to perform voluntary PFM contraction, cognitive or neurological
disorder, uncontrolled hypertension, inability to carry out the
evaluation or treatment, hormone therapy, use of pacemaker or
metal rod implantation [8,14,21,22].
Forty-eight volunteers were recruited, signed an informed
consent and were randomized following a simple randomization
procedure (computerized random numbers) into three groups:
Surface Electrical Stimulation Group (SESG) (n = 15), Intravaginal
Electrical Stimulation Group (IVESG) (n = 16) and Control Group
(CG) (n = 17). A researcher who was not involved in the data
collection or analyses created this randomization list.
2.2. Outcome measures
Only one blinded experienced physiotherapist performed all
evaluations. Initially, all women went through a physical
examination and an interview about their medical history. The
SESG, IVESG and CG were evaluated before and after the treatment
for primary outcomes (urinary leakage and PFM function) and
secondary outcomes (quality of life (QOL)).
The 1-h pad test was performed to evaluate urinary leakage
according to the protocol proposed by Abrams et al. [23]. Thewomen were instructed to wear a pad which had been previously
weighed on a precision balance (Marte Shimadzu BL320, precision
of 0.001 g, Marte) and then drink 500 ml of water. After 30 min,
they started performing a series of provocative exercises and, at
the end of 1 h, the pad was removed and reweighed, and the
urinary loss calculated.
Assessment of PFM strength by digital palpation was carried out
using the PERFECT scheme. The volunteers were positioned supine
with 458 of hip and knee ﬂexion, and the evaluator introduced two
ﬁngers up to one third of the vagina. The volunteer was then
instructed to lift and squeeze the PFM as hard as possible. The
strength measured on the 6-point Modiﬁed Oxford Scale [24].
Evaluation of the PFM contraction pressure was carried out by the
perineometer Peritron 9300 (Cardio Design, Australia), graduated
from 0 to 300 cmH2O. The women were placed in the supine
position, with hip and knee ﬂexion. The vaginal probe was inserted
approximately 3.5 cm into the vaginal cavity and the device was
calibrated. The women were then verbally instructed to perform
three PFM contractions, each of 3 s, with maximum perceived
effort. The women were also instructed to avoid using the
abdominal, gluteal and hip adductor muscles during the contrac-
tions. The average of three contractions’ peaks was used for
analysis.
For the assessment of QOL, the King’s Health Questionnaire
(KHQ) was used [25], as it is a reliable instrument, speciﬁc to assess
QOL of women with UI and validated in Portuguese/Brazilian [26].
This questionnaire consists of 30 questions, divided into nine
individually scored domains. The total score ranges from 0 to 100:
a score of 100 represents the worst possible QOL, and 0 represents
the best possible QOL [25,26].
2.3. Treatment protocol
The SESG and IESG performed 12 individual sessions of ES, two
weekly sessions of 20 min with Dualpex 961 (Quark Medical
Products) equipment. The electric parameters used in both
treatments were: current type: functional electrical stimulation;
frequency: 50 Hz; pulse duration: 700 ms; time: 20 min; 4-s on/8-s
off cycles; rise: 2 s fall: 2 s; stimulation intensity: maximal level
tolerable [7,16]. In the SESG and IESG the women were not
instructed to perform the PFM contraction during the ES. The
treatment of both groups was performed by another physical
therapist that did not participate in the evaluations.
In the SESG the women were positioned supine, with 458 of hip
and knee ﬂexion. In this treatment, four surface electrodes of
silicone (2.0 cm  3.0 cm) were ﬁxed with masking tape. Two
electrodes were placed in the suprapubic region and the other two
electrodes were crossed on the skin and ﬁxed medial to the ischial
tuberosity [16,27]. During the treatment the women used panties.
In the IESG the participants were positioned supine with 458 of
hip and knee ﬂexion for the positioning of an intravaginal
electrode. The intravaginal electrode used was the Dualpex 961
(Quark Medical Products) urogynecological electrode. During the
treatment the volunteers were positioned supine with hip and
knee in a neutral position.
The CG did not receive any treatment during the corresponding
treatment time. Afterwards, CG subjects were referred for physical
therapy treatment.
2.4. Statistical analysis
All statistical analyses were performed using Statistica Statistical
Software 7.0 (StatSoft Inc.). The Shapiro–Wilk test was used
to evaluate the normal distribution, Kruskal–Wallis test to verify
the homogeneity, Wilcoxon nonparametric test for intragroup
analysis, Kruskal–Wallis test for intergroup analysis, and
Table 1
Demographic and clinics characteristics of the study participants (n = 45).
SESG (n = 15) IVESG (n = 15) CG (n = 15)
Age (years) 64.46  8.83 59.86  4.82 60.13  9.35
BMI (kg/m2) 28.28  4.383 28.26  4.26 29.88  3.75
Number of deliveries 2.73  1.66 2.80  0.94 2.66  1.04
Vaginal deliveries 0.86  1.12 1.20  1.14 1.06  0.96
Data presented as mean  standard deviation.
SESG, Surface Electrical Stimulation Group; IVESG, Intravaginal Electrical Stimulation
Group; CG, Control Group.
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cance used was <0.05 and to measure the clinical signiﬁcance of the
data, the effect size and conﬁdence interval (CI) were calculated. The
effect sizes were considered: mild: values <0.20; moderate: 0.25 and
0.75; large: >0.80 [28].
3. Results
Among the 48 women who started the treatment, two from the
CG (13.33%) did not perform the ﬁnal evaluation due to a health
problem and were excluded and substituted by two other
patients. One participant in the IVESG (6.66%) reported dysme-
norrhea and was excluded from this treatment and substituted by
another participant. Forty-ﬁve volunteers completed the study
and were included in the analysis (Fig. 1). No important differenceRandomized 




Analyzed (n=15) Analyzed (
Analys





Values and intragroup and intergroup analysis of urinary leakage and pelvic ﬂoor mus
Pre-tre
One hour pad test (g) SESG 6.28 
IVESG 2.20 
CG 7.33 
Intergroup p value 0.18 
Strength SESG 2.06 
IVESG 2.00 
CG 2.16 
Intergroup p value 0.95 
Pressure (cmH2O) SESG 39.41 
IVESG 37.42 
CG 37.92 
Intergroup p value 0.74 
Data presented as mean  standard deviation.
SESG, Surface Electrical Stimulation Group; IVESG, Intravaginal Electrical Stimulation Grou
a Signiﬁcant differences intragroup between pre-treatment and post-treatment.
b Signiﬁcant differences versus Control Group (Mann–Whitney tests).in any characteristic was found at baseline between the groups
(Table 1).
There was a signiﬁcant reduction in urinary leakage measured
by the 1-h pad test in the SESG (p = 0.01; effect size: 0.21) and
IVESG (p = 0.01; effect size: 0.41) after the treatment. In the CG
there was no signiﬁcant difference in this variable (p = 0.61, effect
size: 0.02). In the intergroup analysis, there was a signiﬁcant
reduction, after the treatment, in the SESG and CG (p = 0.009; effect
size 0.31; 95% CI from 14.61 to 5.99) as well as between IVESG
and CG (p < 0.001; effect size: 0.67: 95% CI from 15.30 to 0.88)
after the treatment (Table 2).
There was a signiﬁcant improvement in muscle strength after
the treatment in the IVESG. The intergroup analysis did not ﬁnd
statistical differences between SESG, IVESG and CG (Table 2). There
was a signiﬁcant increase in perineometry of the PFM in the SESG
and IVESG after treatment. The intergroup analysis did not show
statistical differences between SESG, IVESG and CG (Table 2).
In the evaluation of QOL, there was a signiﬁcant reduction of
scores in different domains, such as: incontinence impact,
limitations of daily activities, physical limitation, emotion, sleep
and disposition and severity in SESG (all p < 0.02; effect size 2.73;
95% CI from 75.46 to 6.96) and IVESG (all p < 0.04; effect size
3.07; 95% CI from 77.27 to 6.40) after the treatments. In relation
to the social limitation there was signiﬁcant improvement after the
treatment only in the IVESG. The intergroup analysis presented
signiﬁcant differences in incontinence impact, limitations of daily(n = 48)








cle strength for the three groups before and after treatment.
atment Post-treatment Intragroup p value
 15.19 3.31  12.10b 0.010a
 4.65 0.41  0.78b 0.010a
 16.02 7.62  15.27 0.61
0.0005
 0.80 2.53  0.83 0.07
 1.00 2.66  0.81 0.007a
 0.83 2.25  0.86 0.99
0.29
 17.65 47.37  19.16 0.004a
 22.89 44.23  20.10 0.04a
 22.95 37.65  19.16 0.58
0.52
p; CG, Control Group.
Table 3
Values of the King’s Health Questionnaire domains for the groups.
Pre-treatment Post-treatment Intragroup p value
General health SESG 40.00  26.39 33.33  32.27 0.68
IVESG 38.33  18.58 26.66  17.59 0.07
CG 37.50  25.00 43.75  21.65 0.61
Intergroup p value 0.74 0.17
Incontinence impact SESG 57.78  32.04 6.66  13.80b 0.0005a
IVESG 64.44  32.03 4.44  11.73b 0.0005a
CG 58.33  37.94 61.11  37.15 0.44
Intergroup p value 0.80 <0.0001
Limitations of daily activities SESG 34.44  42.00 0.00  0.00b 0.01a
IVESG 36.66  26.12 0.00  0.00b 0.001a
CG 56.94  39.85 54.16  40.27 1.00
Intergroup p value 0.39 <0.0001
Physical limitations SESG 43.33  31.37 1.11  4.30b 0.0003a
IVESG 43.33  39.74 1.11  4.30b 0.004a
CG 54.16  44.45 51.38  42.91 0.68
Intergroup p value 0.52 <0.0001
Social limitations SESG 18.52  32.71 1.85  5.00 0.22
IVESG 21.48  31.83 0.00  0.00b 0.02a
CG 33.79  34.85 31.01  36.19 0.68
Intergroup p value 23 0.0007
Personal relationships SESG 4.44  11.73 0.00  0.00b 0.47
IVESG 13.33  35.74 0.00  14.08 0.22
CG 13.88  23.39 22.22  33.58 1.00
Intergroup p value 0.35 0.04
Emotions SESG 28.15  38.23 2.96  8.88b 0.01a
IVESG 48.15  33.77 2.96  7.82b 0.0008a
CG 49.07  32.29 56.48  33.65 0.75
Intergroup p value 0.1548 <0.0001
Sleep and disposition SESG 27.77  41.62 0.00  0.00c 0.02a
IVESG 14.44  28.08 0.00  0.00c 0.07
CG 30.55  43.13 30.55  43.13 0.68
Intergroup p value 0.8140 0.003
Severity measures SESG 37.77  29.67 8.09  14.60b 0.0005a
IVESG 38.66  21.56 1.77  4.69b 0.0003a
CG 47.22  26.12 58.33  25.60 0.75
Intergroup p value 0.7605 <0.0001
Data presented as mean  standard deviation.
SESG, Surface Electrical Stimulation Group; IVESG, Intravaginal Electrical Stimulation Group; CG, Control Group.
a Signiﬁcant differences between pre-treatment and post-treatment.
b Signiﬁcant difference versus Control Group ((Mann–Whitney tests).
c Signiﬁcant differences Surface Electrical Stimulation Group versus Intravaginal Electrical Stimulation Group (Mann–Whitney tests).
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disposition and severity domains when comparing the SESG and
CG, and the IVESG and CG (p < 0.04). In the social relation and sleep
domains there were signiﬁcant differences intergroup analysis,
after the treatment, between the SESG and CG (p = 0.04), and the
SESG and IVESG (<0.001) (Table 3).
4. Comment
In this study, 12 sessions of treatment with SES and IVES were
effective for SUI, demonstrating these to be a good option for
treatment. We observed improvement after IVES treatment in
urinary leakage, strength and pressure of PFM contraction, while
the SESG presented improvement only in urinary leakage and PFM
pressure.
The improvement in the urinary leakage in women treated with
IVES was veriﬁed in other studies [7,29] agreeing with the result of
the present study. In relation to SES treatment, only one study has
veriﬁed the improvement of urinary leakage evaluated by the 1-h
pad test [16].
In relation to the PFM contraction pressure, Dumoulin et al. [14]
also found an increase in the pressure with SES. In the study of
Pereira et al. [16], however, there was no improvement incontraction pressure with the SES treatment, disagreeing with
this study.
In intergroup analysis, there was signiﬁcant difference between
the CG and both the SESG and IVESG in the 1-h pad test after
treatment. There are no studies that compared SES and IVES, only
those that evaluated the difference between an IVESG and a CG
[10,30]. Bø et al. [10] did not ﬁnd intergroup difference in
contraction pressure and pad test, agreeing partially with this
study. Castro et al. [30] veriﬁed a signiﬁcant difference in the 20-
min pad test, agreeing with the present study.
Currently QOL evaluation is considered to be more relevant
than quantitative measurement, because it reﬂects the patients’
satisfaction with the treatment [36,37]. This study found
improvement in many domains of KHQ in both treatment groups.
Two studies veriﬁed improvement in QOL after IVES, but those
studies used another questionnaire, the I-QOL. Only Pereira et al.
[16] evaluated the QOL after SES treatment and found improve-
ment in some domains of KHQ, agreeing with the present study.
In this study the women who underwent treatment with SES or
IVES presented a signiﬁcant decrease in pad test value and
reported an improvement in QOL after the treatment. A possible
explanation for the improvement of SUI is that the ES causes the
pudendal nerve stimulation [6,8]. This stimulus promotes
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[8,31–33]. Another important role of ES is an improvement in the
electric activation, improving the proprioception and coordination
in pelvic ﬂoor contraction during the situations that cause SUI [34].
Moreover the pudendal nerve is an efferent nerve for the
external urethral sphincter [35], so this treatment is capable of
increasing the pressure of urethral closure, improving the SUI.
Another important factor is that the ES increases the blood ﬂow to
the urethra and PFM, improving the neuromuscular connections,
muscular ﬁber function and genital atrophy. So, with these changes
in the PFM there is improvement of the mechanism of urethral
closure and SUI [6,33]. These are two possible explanations for the
result of this study in that it improved the urinary leakage and QOL
without a signiﬁcant difference between the three groups in the
PFM strength and pressure after the treatment.
The position used in this study was described in 1995 by
Dumoulin et al. [14], who compared it with another positioning
and concluded that in this position the current penetrates deeper
within the pelvis. After, Kajbafzadeh et al. [27] used this same
position of electrodes in children with myelomeningocele and
found a good result. In the last study with this position, Pereira
et al. [16] concluded that this treatment improved the SUI and QOL
of women. So, interest in this less invasive treatment seems to be
increasing because it is effective, but it needs more studies.
According to Green et al., IVES is a very invasive treatment in the
patient’s perception, decreasing the acceptance and adherence to
use of this treatment. The use of SES can be more acceptable to the
patients and comfortable for physical therapist [9].
The main limitation of this study was the absence of an
electromyographic evaluation to verify if modiﬁcation in PFM
activation occurs. Another limitation is that we did not utilize
ultrasonography to evaluate if hypertrophy of PFM happens after
the ES treatment.
The clinical application of this study is that SES is an option for
SUI treatment, with good results and many advantages, such as: it
is not necessary sterilize the equipment, it is a cheap treatment, it
is not necessary to use speciﬁc equipment and this treatment can
be used in women, men and children, because it is not invasive.
In conclusion, SES and IVES are important treatments to
improve SUI. Both treatments improved QOL, urinary leakage,
strength and pressure of PFM contraction. Although this is a
preliminary study that compares the SES with the IVES, it opens a
new line of possibilities for further studies. Future research should
include a follow-up period, urodynamic examination and the use
of electromyography.
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